Literature DB >> 11738865

The role of different X-inactivation pattern on the variable clinical phenotype with Rett syndrome.

T Ishii1, Y Makita, A Ogawa, S Amamiya, M Yamamoto, A Miyamoto, J Oki.   

Abstract

A gene for Methyl-CpG binding protein 2 (MECP2), which locates Xq28, was recently found to be responsible for Rett syndrome. Although mutational analyses of MECP2 in Rett syndrome have been extensively analyzed, the mechanism(s) by which variable clinical phenotype occurred between affected monozygotic twins or sisters have not been clarified. We hypothesized that the difference of X-inactivation pattern might explain this phenomenon. With the method based on methylation-specific PCR, we analyzed polymorphic trinucleotide repeat in the human andorogen receptor gene mapped on Xq11.2-12, using DNA samples derived from previously described monozygotic twins and sisters together with their parents. Their clinical phenotypes were reported to be significantly different between siblings. We found that (1) maternally derived allele is predominantly active than paternally derived one in three out of four patients analyzed, (2) remaining one twin patient, whose ratio of active paternal allele is almost the same level as maternal allele, showed far much severe phenotype when compared with her counterpart. Together with the finding that most of the alleles with de novo mutation are from paternal X chromosome in sporadic cases, the existence of a mechanism that suppresses mutated paternal allele activation, resulting skewed X-inactivation to make clinical phenotype milder, might be speculated. Thus, when this mechanism fails to work sufficiently by an unknown reason, severer clinical phenotype could occur.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11738865     DOI: 10.1016/s0387-7604(01)00344-8

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  21 in total

1.  Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation.

Authors:  Hayley Archer; Julie Evans; Helen Leonard; Lyn Colvin; David Ravine; John Christodoulou; Sarah Williamson; Tony Charman; Mark E S Bailey; Julian Sampson; Nicholas de Klerk; Angus Clarke
Journal:  J Med Genet       Date:  2006-08-11       Impact factor: 6.318

2.  β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome.

Authors:  Nikolaos Mellios; Jonathan Woodson; Rodrigo I Garcia; Benjamin Crawford; Jitendra Sharma; Steven D Sheridan; Stephen J Haggarty; Mriganka Sur
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-23       Impact factor: 11.205

3.  Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome.

Authors:  Jorge Castro; Rodrigo I Garcia; Showming Kwok; Abhishek Banerjee; Jeremy Petravicz; Jonathan Woodson; Nikolaos Mellios; Daniela Tropea; Mriganka Sur
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-23       Impact factor: 11.205

4.  X Chromosome-Inactivation Patterns in 31 Individuals with PHACE Syndrome.

Authors:  C T Sullivan; S L Christian; J T C Shieh; D Metry; F Blei; A Krol; B A Drolet; I J Frieden; W B Dobyns; D H Siegel
Journal:  Mol Syndromol       Date:  2012-11-16

Review 5.  Rett syndrome and MeCP2.

Authors:  Vichithra R B Liyanage; Mojgan Rastegar
Journal:  Neuromolecular Med       Date:  2014-03-11       Impact factor: 3.843

Review 6.  Emerging pharmacotherapies for neurodevelopmental disorders.

Authors:  Daniel Z Wetmore; Craig C Garner
Journal:  J Dev Behav Pediatr       Date:  2010-09       Impact factor: 2.225

7.  MECP2 mutations in Czech patients with Rett syndrome and Rett-like phenotypes: novel mutations, genotype-phenotype correlations and validation of high-resolution melting analysis for mutation scanning.

Authors:  Daniela Zahorakova; Petra Lelkova; Vladimir Gregor; Martin Magner; Jiri Zeman; Pavel Martasek
Journal:  J Hum Genet       Date:  2016-03-17       Impact factor: 3.172

8.  Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome.

Authors:  Kun-Yong Kim; Eriona Hysolli; In-Hyun Park
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-01       Impact factor: 11.205

9.  X-chromosome inactivation patterns are unbalanced and affect the phenotypic outcome in a mouse model of rett syndrome.

Authors:  Juan I Young; Huda Y Zoghbi
Journal:  Am J Hum Genet       Date:  2004-02-17       Impact factor: 11.025

Review 10.  MicroRNAs and epigenetic regulation in the mammalian inner ear: implications for deafness.

Authors:  Lilach M Friedman; Karen B Avraham
Journal:  Mamm Genome       Date:  2009-10-30       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.